Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Biol Psychiatry. 2014 Apr 25;77(5):475–487. doi: 10.1016/j.biopsych.2014.04.009

Figure 2. Effects of Δ9-THC in paclitaxel-treated WT mice.

Figure 2

(A, B) Δ9-THC (5 or 10 mg/kg/day i.p.) attenuated paclitaxel-induced (A) mechanical and (B) cold allodynia in WT (C57BL/6J) mice in a dose- and time-dependent manner. (C, D) Δ9-THC (5 or 10 mg/kg/day i.p.) decreased (C) motor performance and (D) body temperature in paclitaxel-treated WT mice relative to vehicle on treatment day 2, but not day 7. (E) Δ9-THC (5 or 10 mg/kg/day i.p.) produced withdrawal symptoms when challenged with the CB1 antagonist rimonabant. BL, pre-paclitaxel baseline; PTX, post-paclitaxel baseline. Data are expressed as mean ± SEM (n=5–6 per group). *P<0.05 vs. vehicle, +P<0.05 vs. Δ9-THC (10 mg/kg/day i.p.), xP<0.05 vs. Veh+Rim (chronic vehicle and challenge by rimonabant), $P<0.05 vs. Veh+Veh (chronic vehicle and challenge by vehicle), one-way ANOVA followed by Bonferroni post hoc test or two-tailed t-test. #P<0.05 vs. BL, repeated measures ANOVA.